<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>8(11)</volume><submitter>Gallegos AC</submitter><pubmed_abstract>Objective: There are no safety or absorption studies to guide topical timolol therapy for treatment of chronic wounds. This study was undertaken to address this gap. Approach: A prospective, observational, cross-sectional comparative study of timolol plasma levels in patients after topical administration to a chronic wound, compared with levels in patients after timolol ocular administration for the indication of glaucoma. Results: There was no statistically significant difference in the average plasma level of timolol in wound as compared with glaucoma patients. No bradycardia or wheezing was observed after administration. Innovation: We determined the single time point concentration of timolol in plasma 1 h after application of timolol 0.5% gel-forming solution to debrided chronic wounds</pubmed_abstract><journal>Advances in wound care</journal><pagination>538-545</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC6798797</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Absorption and Safety of Topically Applied Timolol for Treatment of Chronic Cutaneous Wounds.</pubmed_title><pmcid>PMC6798797</pmcid><pubmed_authors>West K</pubmed_authors><pubmed_authors>Peavy TR</pubmed_authors><pubmed_authors>Dixon RW</pubmed_authors><pubmed_authors>Isseroff RR</pubmed_authors><pubmed_authors>Tchanque-Fossuo CN</pubmed_authors><pubmed_authors>Patel RP</pubmed_authors><pubmed_authors>Gallegos AC</pubmed_authors><pubmed_authors>Dahle SE</pubmed_authors><pubmed_authors>Davis MJ</pubmed_authors><pubmed_authors>Eisentrout-Melton A</pubmed_authors></additional><is_claimable>false</is_claimable><name>Absorption and Safety of Topically Applied Timolol for Treatment of Chronic Cutaneous Wounds.</name><description>Objective: There are no safety or absorption studies to guide topical timolol therapy for treatment of chronic wounds. This study was undertaken to address this gap. Approach: A prospective, observational, cross-sectional comparative study of timolol plasma levels in patients after topical administration to a chronic wound, compared with levels in patients after timolol ocular administration for the indication of glaucoma. Results: There was no statistically significant difference in the average plasma level of timolol in wound as compared with glaucoma patients. No bradycardia or wheezing was observed after administration. Innovation: We determined the single time point concentration of timolol in plasma 1 h after application of timolol 0.5% gel-forming solution to debrided chronic wounds</description><dates><release>2019-01-01T00:00:00Z</release><publication>2019 Nov</publication><modification>2025-04-26T16:49:39.569Z</modification><creation>2019-11-05T08:08:00Z</creation></dates><accession>S-EPMC6798797</accession><cross_references><pubmed>31637100</pubmed><doi>10.1089/wound.2019.0970</doi></cross_references></HashMap>